Last reviewed · How we verify
JE-CV Vaccine
JE-CV is a chimeric vaccine that combines the live attenuated Japanese encephalitis virus backbone with dengue virus structural proteins to provide protection against both Japanese encephalitis and dengue viruses.
JE-CV is a chimeric vaccine that combines the live attenuated Japanese encephalitis virus backbone with dengue virus structural proteins to provide protection against both Japanese encephalitis and dengue viruses. Used for Prevention of Japanese encephalitis and dengue fever in endemic regions.
At a glance
| Generic name | JE-CV Vaccine |
|---|---|
| Also known as | IMOJEV |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated chimeric vaccine |
| Target | Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a recombinant approach where the Japanese encephalitis virus (JEV) genome is modified to express dengue virus (DENV) structural proteins (prM and E), creating a tetravalent vaccine candidate against all four dengue serotypes while maintaining JEV immunity. This chimeric strategy leverages the established safety profile of the live attenuated JE vaccine platform while expanding protection to dengue, which shares similar transmission vectors and geographic distribution in endemic regions.
Approved indications
- Prevention of Japanese encephalitis and dengue fever in endemic regions
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV (PHASE3)
- Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers (PHASE3)
- Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine (NA)
- Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines (PHASE3)
- Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children (PHASE2)
- Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers (PHASE3)
- A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers (PHASE3)
- Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JE-CV Vaccine CI brief — competitive landscape report
- JE-CV Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI